Search
Fish oil
go.drugbank.com/drugs/DB13961ApprovedInvestigationalNutraceuticaldemonstrated abilities in minimizing or preventing hypertriglyceridemia when taken as an adjunct to a healthy diet [FDA Label]. … Fish oil is a component of SMOFLIPID, which was FDA approved in July 2016.
Mixtures: Protect Cardio AFCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesNipocalimab
go.drugbank.com/drugs/DB16257ApprovedInvestigationalNipocalimab-aahu is a neonatal Fc receptor (FcRn) blocker used to treat certain antibody-mediated autoimmune diseases. … [L64042] It is an aglycosylated, fully human IgG1 monoclonal antibody that binds FcRn and blocks the receptor's recycling of immunoglobulin G (IgG), thereby lowering circulating IgG levels, including pathogenic
Methenamine
go.drugbank.com/drugs/DB06799ApprovedInvestigationalVet approvedMethenamine is a heterocyclic organic compound with a cage-like structure similar to adamantane.
Benserazide
go.drugbank.com/drugs/DB12783ApprovedInvestigationalMoreover, the European Medcines Agency has conferred an orphan designation upon benseraside since 2015 for its potential to be used as a therapy for beta thalassaemia as well [F3]. … When levodopa is used by itself as a therapy for treating Parkinson's disease, its ubiquitous metabolism into dopamine is responsible for a resultant increase in the levels of circulating dopamine in the
Mixtures: LEVODOPA P BENS AL 100/25, LEVODOPA P BENS AL 100/25Zoledronic acid
go.drugbank.com/drugs/DB00399ApprovedInvestigationalZoledronic acid, or CGP 42'446,[A203120] is a third generation, nitrogen containing bisphosphonate similar to [ibandronic acid], [minodronic acid], and [risedronic acid].
Products: Zoledronic Acid - A, ZOLEDRONSAEURE AL 4MG/5MLMF-300
go.drugbank.com/drugs/DB32060InvestigationalAs a potential candidate for the treatment of sarcopenia, it has undergone phase 1 studies to evaluate safety, tolerability, and PK/PD characteristics.[A275368,L54983] … MF-300 is an investigational, first-in-class, small molecule inhibitor of 15-hydroxyprostaglandin dehydrogenase.
Vamotinib
go.drugbank.com/drugs/DB15396InvestigationalVamotinib (PF-114) is under investigation in clinical trial NCT02885766 (Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administration in Adults With … Ph+ Chronic Myeloid Leukemia, Which is Resistant to the 2-nd Generation Bcr-Abl Inhibitors or Has T315I Mutation in the BCR-ABL Gene).
MKC1106-PP
go.drugbank.com/drugs/DB06030ExperimentalMKC1106-PP is a 3-component investigational vaccine made up of a DNA plasmid (pPRA-PSM) and 2 peptides E-PRA and E-PSM. … MKC1106-PP was under investigation in clinical trial NCT00423254 (Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-PP) for Patients With Advanced Cancer.).
Molibresib
go.drugbank.com/drugs/DB16239InvestigationalMolibresib is under investigation in clinical trial NCT01943851 (A Dose Escalation Study to Investigate the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD) and Clinical Activity of GSK525762 in Subjects
Ruxolitinib
go.drugbank.com/drugs/DB08877ApprovedInvestigationalRuxolitinib, formerly known as INCB018424 or INC424, is an anticancer drug and a Janus kinase (JAK) inhibitor. … a treatment for COVID-19.
Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index